Sixty minutes opdivo, page-2

Hi Whats

Yeah frustrating to see the excellent results CAVATAK has achieved fail to sustain an upward share price. We are stuck in a mid .80 to $1.30 trading range which is still well above the level a couple of years back. You would think the share price will take-off at some point...usually when you least expect it. The traders have done better than the holders to this point...we'll see if that trend continues.

As for the medical benefits of CAVATAK and the combinations we have been running with YERVOY and KEYTRUDA so far in clinical trials, there is hope on the horizon for many cancer suffers. As much as we like to make money, to see people getting better and living longer is a wonderful thing.

Cheers